# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...
Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...
Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.
Goldman Sachs analyst Richard Law initiates coverage on MoonLake (NASDAQ:MLTX) with a Neutral rating and announces Price Tar...
https://www.betaville.co.uk/betaville-intelligence/uncooked-alert-moonlake-immunotherapeutics-said-to/